Japan, Sept. 18 -- ATHENA PHARMACEUTIQUES SAS has got intellectual property rights for 'LISDEXAMFETAMINE DIMESYLATE ORALLY DISPERSIBLE TABLET AND PROCESS FOR PREPARATION THEREOF.' Other related details are as follows:
Application Number: JP,2024-195503
Category (FI): A61K47/32,A61K31/165,A61K47/26,A61K47/38,A61P25/20,A61K47/04,A61K47/36,A61K47/10,A61P25/00,A61P25/14,A61K47/12,A61K47/02,A61K9/20
Stage: PROBLEM TO BE SOLVED: To provide a lisdexamfetamine dimesylate orally dispensible tablet, and to provide a process for preparation thereof.SOLUTION: The process for preparation of the lisdexamfetamine dimesylate orally dispensible tablet includes: co-sieving lisdexamfetamine dimesylate, a binder, and a diluent; dry-mixing and blending the sieved lisdexamfetamine dimesylate, the binder, and the diluent to form a blended dry mixture; co-sieving and blending the diluent, a buffer, a disintegrant, a sweetener, and an antistatic agent to prepare an intermediate blend; blending the blended dry mixture with the intermediate blend; lubricating the blended dry mixture with the intermediate blend to form drug granules ready for compression; and compressing the ready-to-compress drug granules to form a compressed lisdexamfetamine dimesylate orally dispensible tablet.SELECTED DRAWING: Figure 1 (Grant)
Filing Date: Nov. 7, 2024
Publication Date: Oct. 14, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
